| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 21, 2017Revenue of $7.1 Billion; GAAP Diluted EPS of $1.48; Non-GAAP Diluted EPS of $1.07
DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2018, which ended October 27, 2017. The company reported second...
-
Aug 28, 2017Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure
DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a...
-
Aug 1, 2017Data from Landmark Trial Published in the Journal of the American Heart Association
DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
-
Jul 11, 2017
DUBLIN - July 11, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing...
-
Apr 25, 2017Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results...